Progressive familial intrahepatic cholestasis (PFIC) type 1 is a hereditary disease characterized by impaired fat digestion and absorption of fat-soluble vitamins, which leads to accumulation of bile in the liver. This autoimmune disorder most often manifests itself in childhood and adolescence and is associated with damage to the bile ducts, which causes their obstruction and leads to fibrotic changes in the liver. The main pathological process is the deficiency of transport proteins responsible for the removal of bile acids from hepatocytes, which causes significant damage to the liver and can lead to cirrhosis. Relatively recent studies emphasize the importance of early diagnosis and a comprehensive approach to the treatment of this disease to reduce the risk of its complications and improve the quality of life of patients.
History of the disease and interesting historical facts
PFVHD was first described in 1959 as a rare form of cholestasis, mainly observed in women during childhood. Historically, this disease was studied as part of a larger group of inherited disorders affecting the bile ducts. In the 1990s, studies were conducted to identify a genetic predisposition to this disease. In 1997, a link was established between PFVHD and a mutation in the ABCB11 gene, which opened new horizons for diagnosis and treatment. Interestingly, at some points, especially in the early 20th century, PFVHD was classified as a cirrhotic disease, which made its diagnosis and understanding of the mechanism of pathogenesis difficult.
Epidemiology
PFVHD type 1 is considered a rare disease, with a population prevalence of 1 in 50,000 to 1 in 100,000 people. Affected individuals are predominantly female, with the male to female ratio being approximately 1:9. In some regions, such as Scandinavia, the incidence rate may be higher, suggesting possible genetic factors contributing to its development. Research suggests that the disease may be more common among a group of individuals with potential hereditary risk factors. Certain populations, particularly those with a strong family history of liver disease, have been shown to have an increased incidence of PFVHD.
Genetic predisposition to this disease
Genetic predisposition to PFVHD type 1 is largely due to mutations in the ABCB11 gene, which codes for a protein responsible for transporting bile acids from hepatocytes to the bile ducts. Other genes involved include ABCB4 and ATP8B1, which also play a key role in the bile flow mechanism. There are different types of mutations, including nonsense mutations and small deletions, which can lead to complete or partial loss of function of these proteins. Patients with PFVHD often have a family history, demonstrating an autosomal recessive pattern of inheritance. Genetic testing can be useful to confirm the diagnosis, especially in cases where the diseases are complex and multifactorial.
Risk factors for the development of this disease
Risk factors for the development of PFVHD type 1 can be divided into genetic and environmental. The main risk factors include:
- The presence of close relatives with similar diseases, which confirms the genetic component.
- Autoimmune diseases such as Sjogren's syndrome or thyroiditis, which may accompany cholestasis.
- Environmental influences, such as exposure to toxins or certain medications that can damage the liver.
- Complex metabolic conditions that can impede bile excretion processes.
- Adolescent girls are particularly susceptible to developing PFVHD, which may be associated with changes in hormonal levels.
Diagnosis of this disease
Diagnosis of PFVHD type 1 includes many stages:
- The main symptoms include jaundice, itching, fatigue and digestive problems.
- Laboratory studies reveal elevated levels of bilirubin and liver transaminases, as well as altered serum bile acid levels.
- Radiological tests such as ultrasound and MRI can help visualize changes in the liver and bile ducts.
- Genetic testing can confirm the presence of specific mutations associated with the disease.
- Differential diagnosis is important to exclude other liver diseases such as hepatitis, cirrhosis and mechanical biliary obstruction.
Treatment
Treatment of progressive familial intrahepatic cholestasis type 1 depends on the stage of the disease and the general condition of the patient:
- General treatment includes supportive measures such as diet, fat restriction and vitamin restriction.
- Pharmacological treatment is aimed at reducing bilirubin levels and improving bile excretion. Ursodeoxycholic acid and other drugs are used.
- Surgery may be necessary in case of complications such as gallstones or bile duct obstruction.
- Other treatments include immunosuppressive drugs to control autoimmune processes.
List of medications used to treat this disease
Some of the medications most commonly prescribed for PFVHD include:
- Urdoxa - ursodeoxycholic acid for improving bile transport.
- Rifampicin to lower liver enzymes.
- Lactulose to correct intestinal microflora and improve digestion.
- Immunosuppressive drugs such as prednisolone if there is an autoimmune component.
Disease monitoring
Monitoring of patients with PFVHD includes regular liver function tests, bilirubin levels, and biliary imaging. Prognosis depends on the severity of the disease and the adequacy of treatment; in many cases, progression can be slowed and quality of life improved. Complications may include cirrhosis, portal hypertension, and the risk of liver cancer, highlighting the need for close monitoring.
Age-related features of the disease
PFVHD can present at any age, but is most often first diagnosed in childhood. In children, the disease may present with pronounced symptoms of jaundice and itching. In adolescents and young adults, the disease may be more asymptomatic, making diagnosis more difficult. In adult patients, liver changes can be significant and often require more aggressive treatment, including liver transplantation in cases of incurable cirrhosis.
Questions and Answers
- What symptoms may indicate PFVHD type 1? Symptoms may include jaundice, itching, fatigue, right upper quadrant pain, and indigestion.
- How is the diagnosis of PFVHD type 1 confirmed? The diagnosis is confirmed by laboratory tests, genetic testing and radiological examination of the liver and bile ducts.
- What is the treatment for PFVHD type 1? Treatment includes medications, supportive care, and, in some cases, surgery.
- Is there a risk of complications with PFVHD type 1? Yes, complications such as liver cirrhosis and the risk of developing liver cancer if the disease continues for a long time are possible.
- How often do I need to undergo follow-up examinations? It is recommended to undergo follow-up examinations at least once every 3-6 months to monitor liver function.
